Brief

On 12/02/2025, the Medicines and Healthcare products Regulatory Agency (MHRA) issued an update regarding Medical imaging agent gozetotide approved for prostate cancer. The MHRA has approved gozetotide, brand name Illuccix, to be used in PET scans for detecting specific types of cancer cells in adults with prostate cancer.

This content is restricted.

Highlights content goes here...

This content is restricted.

Medicines and Healthcare products Regulatory Agency (MHRA)

Quick Insight
RADA.AI
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Enter your registered username/email id.

Enter your Email

Enter your email id below to signup.
Individual Plan
$125 / month OR $1250 / year
Features
Best for: Researchers, Legal professionals, Academics
Enterprise Plan
Contact for Pricing
Features
Best for: Law Firms, Corporations, Government Bodies